Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo - PubMed (original) (raw)

. 2000 Sep 15;60(18):5165-70.

Affiliations

PMID: 11016644

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

L M Butler et al. Cancer Res. 2000.

Abstract

Suberoylanilide hydroxamic acid (SAHA) is the prototype of a family of hybrid polar compounds that induce growth arrest in transformed cells and show promise for the treatment of cancer. SAHA induces differentiation and/or apoptosis in certain transformed cells in culture and is a potent inhibitor of histone deacetylases. In this study, we examined the effects of SAHA on the growth of human prostate cancer cells in culture and on the growth of the CWR22 human prostate xenograft in nude mice. SAHA suppressed the growth of the LNCaP, PC-3, and TSU-Pr1 cell lines at micromolar concentrations (2.5-7.5 microM). SAHA induced dose-dependent cell death in the LNCaP cells. In mice with transplanted CWR222 human prostate tumors, SAHA (25, 50, and 100 mg/kg/day) caused significant suppression of tumor growth compared with mice receiving vehicle alone; treatment with 50 mg/kg/day resulted in a 97% reduction in the mean final tumor volume compared with controls. At this dose, there was no detectable toxicity as evaluated by weight gain and necropsy examination. Increased accumulation of acetylated core histones was detected in the CWR22 tumors within 6 h of SAHA administration. SAHA induced prostate-specific antigen mRNA expression in CWR22 prostate cancer cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.

PubMed Disclaimer

Cited by

Prostatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis a.
Chachadi VB, Ali MF, Cheng PW. Chachadi VB, et al. PLoS One. 2013;8(2):e57416. doi: 10.1371/journal.pone.0057416. Epub 2013 Feb 22. PLoS One. 2013. PMID: 23451223 Free PMC article.
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Gui CY, et al. Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6. doi: 10.1073/pnas.0307708100. Epub 2004 Jan 20. Proc Natl Acad Sci U S A. 2004. PMID: 14734806 Free PMC article.
A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells.
Richa S, Dey P, Park C, Yang J, Son JY, Park JH, Lee SH, Ahn MY, Kim IS, Moon HR, Kim HS. Richa S, et al. Biomol Ther (Seoul). 2020 Mar 1;28(2):184-194. doi: 10.4062/biomolther.2019.074. Biomol Ther (Seoul). 2020. PMID: 31476841 Free PMC article.
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.
Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Myzak MC, et al. Carcinogenesis. 2006 Apr;27(4):811-9. doi: 10.1093/carcin/bgi265. Epub 2005 Nov 9. Carcinogenesis. 2006. PMID: 16280330 Free PMC article.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.
Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. Stamatopoulos B, et al. Haematologica. 2010 Jul;95(7):1136-43. doi: 10.3324/haematol.2009.013847. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145270 Free PMC article.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo - PubMed (original) (raw)